Effects of montelukast treatment on clinical and inflammatory variables in patients with cystic fibrosis (Q46797925)

25 December 2017

title

Effects of montelukast treatment on clinical and inflammatory variables in patients with cystic fibrosis (English)

1 reference

25 December 2017

0 references

6

Joanna Jerzynska

1 reference

25 December 2017

Iwona Stelmach

1

Iwona Stelmach

1 reference

25 December 2017

Paweł Majak

4

Pawel Majak

1 reference

25 December 2017

Tomasz Grzelewski

5

Tomasz Grzelewski

1 reference

25 December 2017

Wlodzimierz Stelmach

3

Wlodzimierz Stelmach

1 reference

25 December 2017

author name string

Aleksandra Korzeniewska

2

1 reference

25 December 2017

publication date

1 October 2005

1 reference

25 December 2017

Annals of Allergy, Asthma & Immunology

published in

1 reference

25 December 2017

volume

95

1 reference

25 December 2017

issue

4

1 reference

25 December 2017

page(s)

372-380

1 reference

25 December 2017

The role of inflammation in the pathophysiology of CF lung disease

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961156-8

7 January 2021

Inflammatory cytokines in cystic fibrosis lungs

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961156-8

7 January 2021

Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961156-8

7 January 2021

Myeloperoxidase and protein oxidation in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961156-8

7 January 2021

Interleukin-8 Concentrations Are Elevated in Bronchoalveolar Lavage, Sputum, and Sera of Children with Cystic Fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961156-8

7 January 2021

Eosinophilic activation in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961156-8

7 January 2021

Sputum tumour necrosis factor-alpha and leukotriene concentrations in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961156-8

7 January 2021

Leukotrienes in the sputum and urine of cystic fibrosis children

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961156-8

7 January 2021

Sputum cysteinyl‐leukotriene levels correlate with the severity of pulmonary disease in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961156-8

7 January 2021

Leukotrienes and Inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961156-8

7 January 2021

Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961156-8

7 January 2021

Leukotrienes as Mediators of Airway Obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961156-8

7 January 2021

Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961156-8

7 January 2021

Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961156-8

7 January 2021

Eosinophil chemotaxis inhibited by 5-lipoxygenase blockade and leukotriene receptor antagonism

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961156-8

7 January 2021

Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961156-8

7 January 2021

Cytokine concentrations in sputum from patients with cystic fibrosis and their relation to eosinophil activity

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961156-8

7 January 2021

Anti-inflammatory effects of montelukast in mild cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961156-8

7 January 2021

Montelukast sodium in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961156-8

7 January 2021

A pilot study of zafirlukast as an anti-inflammatory agent in the treatment of adults with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961156-8

7 January 2021

Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961156-8

7 January 2021

A randomized, double-blind trial of the effect of treatment with montelukast on bronchial hyperresponsiveness and serum eosinophilic cationic protein (ECP), soluble interleukin 2 receptor (sIL-2R), IL-4, and soluble intercellular adhesion molecule 1

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961156-8

7 January 2021

A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. Montelukast Asthma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961156-8

7 January 2021

Serum eosinophil cationic protein, eosinophil protein X and eosinophil peroxidase in relation to pulmonary function in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961156-8

7 January 2021

Major basic protein, but not eosinophil cationic protein or eosinophil protein X, is related to atopy in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961156-8

7 January 2021

Increased degranulation of eosinophil and neutrophil granulocytes in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961156-8

7 January 2021

Regulation of proteoglycan synthesis by leukotriene d4 and epidermal growth factor in bronchial smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961156-8

7 January 2021

Effects of ONO-1078 (pranlukast) on cytokine production in peripheral blood mononuclear cells of patients with bronchial asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961156-8

7 January 2021

A randomized, double-blind trial of the effect of glucocorticoid, antileukotriene and beta-agonist treatment on IL-10 serum levels in children with asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961156-8

7 January 2021

Altered respiratory epithelial cell cytokine production in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961156-8

7 January 2021

Interleukin-10 and the interleukin-10 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961156-8

7 January 2021

TNF-alpha, IL-8, soluble ICAM-1, and neutrophils in sputum of cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961156-8

7 January 2021

Relationship between disease severity and inflammatory markers in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961156-8

7 January 2021

Determination of leukotriene effects on human neutrophil chemotaxis in vitro by differential assessment of cell motility and polarity.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961156-8

7 January 2021

Asthma control and patient satisfaction among early pediatric users of montelukast

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961156-8

7 January 2021

10.1016/S1081-1206(10)61156-8

Identifiers

DOI

1 reference

25 December 2017

1 reference

25 December 2017